A concurrent dual analysis of genomic data augments diagnoses: Experiences of 2 clinical sites in the Undiagnosed Diseases Network

Published:December 04, 2022DOI:



      Next-generation sequencing (NGS) has revolutionized the diagnostic process for rare/ultrarare conditions. However, diagnosis rates differ between analytical pipelines. In the National Institutes of Health-Undiagnosed Diseases Network (UDN) study, each individual’s NGS data are concurrently analyzed by the UDN sequencing core laboratory and the clinical sites. We examined the outcomes of this practice.


      A retrospective review was performed at 2 UDN clinical sites to compare the variants and diagnoses/candidate genes identified with the dual analyses of the NGS data.


      In total, 95 individuals had 100 diagnoses/candidate genes. There was 59% concordance between the UDN sequencing core laboratories and the clinical sites in identifying diagnoses/candidate genes. The core laboratory provided more diagnoses, whereas the clinical sites prioritized more research variants/candidate genes (P < .001). The clinical sites solely identified 15% of the diagnoses/candidate genes. The differences between the 2 pipelines were more often because of variant prioritization disparities than variant detection.


      The unique dual analysis of NGS data in the UDN synergistically enhances outcomes. The core laboratory provided a clinical analysis with more diagnoses and the clinical sites prioritized more research variants/candidate genes. Implementing such concurrent dual analyses in other genomic research studies and clinical settings can improve both variant detection and prioritization.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      ACMG Member Login

      Are you an ACMG Member? Sign in for online access.


      Subscribe to Genetics in Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chong J.X.
        • Buckingham K.J.
        • Jhangiani S.N.
        • et al.
        The genetic basis of Mendelian phenotypes: discoveries, challenges, and opportunities.
        Am J Hum Genet. 2015; 97: 199-215
        • Splinter K.
        • Adams D.R.
        • Bacino C.A.
        • et al.
        Effect of genetic diagnosis on patients with previously undiagnosed disease.
        NEngl J Med. 2018; 379: 2131-2139
        • Need A.C.
        • Shashi V.
        • Hitomi Y.
        • et al.
        Clinical application of exome sequencing in undiagnosed genetic conditions.
        J Med Genet. 2012; 49: 353-361
        • Yang Y.
        • Muzny D.M.
        • Reid J.G.
        • et al.
        Clinical whole-exome sequencing for the diagnosis of Mendelian disorders.
        N Engl J Med. 2013; 369: 1502-1511
        • Yang Y.
        • Muzny D.M.
        • Xia F.
        • et al.
        Molecular findings among patients referred for clinical whole-exome sequencing.
        JAMA. 2014; 312: 1870-1879
        • Lee H.
        • Deignan J.L.
        • Dorrani N.
        • et al.
        Clinical exome sequencing for genetic identification of rare Mendelian disorders.
        JAMA. 2014; 312: 1880-1887
        • Sawyer S.L.
        • Hartley T.
        • Dyment D.A.
        • et al.
        Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care.
        Clin Genet. 2016; 89: 275-284
        • Shickh S.
        • Mighton C.
        • Uleryk E.
        • Pechlivanoglou P.
        • Bombard Y.
        The clinical utility of exome and genome sequencing across clinical indications: a systematic review.
        Hum Genet. 2021; 140: 1403-1416
        • Lionel A.C.
        • Costain G.
        • Monfared N.
        • et al.
        Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test.
        Genet Med. 2018; 20: 435-443
        • Sanford E.F.
        • Clark M.M.
        • Farnaes L.
        • et al.
        Rapid whole genome sequencing has clinical utility in children in the PICU.
        Pediatr Crit Care Med. 2019; 20: 1007-1020
        • Willig L.K.
        • Petrikin J.E.
        • Smith L.D.
        • et al.
        Whole-genome sequencing for identification of Mendelian disorders in critically ill infants: a retrospective analysis of diagnostic and clinical findings.
        Lancet Respir Med. 2015; 3: 377-387
        • Gilissen C.
        • Hehir-Kwa J.Y.
        • Thung D.T.
        • et al.
        Genome sequencing identifies major causes of severe intellectual disability.
        Nature. 2014; 511: 344-347
        • Liu P.
        • Meng L.
        • Normand E.A.
        • et al.
        Reanalysis of clinical exome sequencing Data.
        N Engl J Med. 2019; 380: 2478-2480
        • French C.E.
        • Delon I.
        • Dolling H.
        • et al.
        Whole genome sequencing reveals that genetic conditions are frequent in intensively ill children.
        Intensive Care Med. 2019; 45: 627-636
        • Shashi V.
        • Schoch K.
        • Spillmann R.
        • et al.
        A comprehensive iterative approach is highly effective in diagnosing individuals who are exome negative.
        Genet Med. 2019; 21: 161-172
        • Eldomery M.K.
        • Coban-Akdemir Z.
        • Harel T.
        • et al.
        Lessons learned from additional research analyses of unsolved clinical exome cases.
        Genome Med. 2017; 9: 26
        • Need A.C.
        • Shashi V.
        • Schoch K.
        • Petrovski S.
        • Goldstein D.B.
        The importance of dynamic re-analysis in diagnostic whole exome sequencing.
        J Med Genet. 2017; 54: 155-156
        • Schobers G.
        • Schieving J.H.
        • Yntema H.G.
        • et al.
        Reanalysis of exome negative patients with rare disease: a pragmatic workflow for diagnostic applications.
        Genome Med. 2022; 14: 66
        • Wenger A.M.
        • Guturu H.
        • Bernstein J.A.
        • Bejerano G.
        Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providers.
        Genet Med. 2017; 19: 209-214
        • Ewans L.J.
        • Schofield D.
        • Shrestha R.
        • et al.
        Whole-exome sequencing reanalysis at 12 months boosts diagnosis and is cost-effective when applied early in Mendelian disorders.
        Genet Med. 2018; 20: 1564-1574
        • Hiatt S.M.
        • Amaral M.D.
        • Bowling K.M.
        • et al.
        Systematic reanalysis of genomic data improves quality of variant interpretation.
        Clin Genet. 2018; 94: 174-178
        • Salfati E.L.
        • Spencer E.G.
        • Topol S.E.
        • et al.
        Re-analysis of whole-exome sequencing data uncovers novel diagnostic variants and improves molecular diagnostic yields for sudden death and idiopathic diseases.
        Genome Med. 2019; 11: 83
        • Genetics Initiative Epilepsy
        The Epilepsy Genetics Initiative: systematic reanalysis of diagnostic exomes increases yield.
        Epilepsia. 2019; 60: 797-806
        • Schoch K.
        • Esteves C.
        • Bican A.
        • et al.
        Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science.
        Genet Med. 2021; 23: 259-271
        • O’Rawe J.
        • Jiang T.
        • Sun G.
        • et al.
        Low concordance of multiple variant-calling pipelines: practical implications for exome and genome sequencing.
        Genome Med. 2013; 5: 28
        • Roy S.
        • Coldren C.
        • Karunamurthy A.
        • et al.
        Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the Association for Molecular Pathology and the College of American Pathologists.
        J Mol Diagn. 2018; 20: 4-27
        • Rosenfeld J.A.
        • Mason C.E.
        • Smith T.M.
        Limitations of the human reference genome for personalized genomics.
        PLoS One. 2012; 7e40294
        • Brownstein C.A.
        • Beggs A.H.
        • Homer N.
        • et al.
        An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge.
        Genome Biol. 2014; 15: R53
        • Bick D.
        • Fraser P.C.
        • Gutzeit M.F.
        • et al.
        Successful application of whole genome sequencing in a medical genetics clinic.
        J Pediatr Genet. 2017; 6: 61-76
        • Dewey F.E.
        • Grove M.E.
        • Priest J.R.
        • et al.
        Sequence to medical phenotypes: a framework for interpretation of human whole genome DNA sequence data.
        PLoS Genet. 2015; 11e1005496
        • Geoffroy V.
        • Guignard T.
        • Kress A.
        • et al.
        AnnotSV and knotAnnotSV: a web server for human structural variations annotations, ranking and analysis.
        Nucleic Acids Res. 2021; 49: W21-W28
        • Smedley D.
        • Jacobsen J.O.B.
        • Jäger M.
        • et al.
        Next-generation diagnostics and disease-gene discovery with the Exomiser.
        Nat Protoc. 2015; 10: 2004-2015
        • Schoch K.
        • Tan Q.K.G.
        • Stong N.
        • et al.
        Alternative transcripts in variant interpretation: the potential for missed diagnoses and misdiagnoses.
        Genet Med. 2020; 22: 1269-1275
        • Shashi V.
        • Geist J.
        • Lee Y.
        • et al.
        Heterozygous variants in MYBPC1 are associated with an expanded neuromuscular phenotype beyond arthrogryposis.
        Hum Mutat. 2019; 40: 1115-1126
        • Rodan L.H.
        • Spillmann R.C.
        • Kurata H.T.
        • et al.
        Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations.
        Genet Med. 2021; 23 (Published correction appears in Genet Med. 2021;23(10):2016. 1922-1932
        • Luo X.
        • Schoch K.
        • Jangam S.V.
        • et al.
        Rare deleterious de novo missense variants in Rnf2/Ring2 are associated with a neurodevelopmental disorder with unique clinical features.
        Hum Mol Genet. 2021; 30: 1283-1292
        • Barish S.
        • Senturk M.
        • Schoch K.
        • et al.
        The microRNA processor DROSHA is a candidate gene for a severe progressive neurological disorder.
        Hum Mol Genet. 2022; 31: 2934-2950
        • Hehir-Kwa J.Y.
        • Pfundt R.
        • Veltman J.A.
        Exome sequencing and whole genome sequencing for the detection of copy number variation.
        Expert Rev Mol Diagn. 2015; 15: 1023-1032
        • Wright C.F.
        • McRae J.F.
        • Clayton S.
        • et al.
        Making new genetic diagnoses with old data: iterative reanalysis and reporting from genome-wide data in 1,133 families with developmental disorders.
        Genet Med. 2018; 20: 1216-1223